
Neoleukin Therapeutics NLTX
$ 3.49
0.0%
Quarterly report 2024-Q3
added 11-18-2024
Country |
![]() |
IPO year |
2014 |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Jonathan Drachman |
Employees in the company |
65 |
Shares |
492 K |
Market Cap[1] |
$ 193 M |
EBITDA (LTM) |
$ -66.9 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Drug manufacturers"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.